טוען...

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks. This phase IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in fo...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuropsychopharmacology
Main Authors: Sanacora, Gerard, Johnson, Michael R, Khan, Arif, Atkinson, Sarah D, Riesenberg, Robert R, Schronen, Juan P, Burke, Michael A, Zajecka, John M, Barra, Luis, Su, Hong-Lin, Posener, Joel A, Bui, Khanh H, Quirk, Michael C, Piser, Timothy M, Mathew, Sanjay J, Pathak, Sanjeev
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2017
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312066/
https://ncbi.nlm.nih.gov/pubmed/27681442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2016.224
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!